Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Indivior plc
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Keeping Track: Immunology Drives US FDA Action, With Approvals For AZ/Amgen’s Tezspire, Argenx’s Vyvgart, And New JAK Uses
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
Other companies have largely halted practices at issue in the ‘diabolical anticompetitive plan’ undertaken by Shkreli’s former firm. FTC did not challenge the price hike for Daraprim itself, but did cite an effort to block release of sales data and other tactics to discourage generics.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Indivior Inc.
- Indivior UK Limited
- Reckitt Benckiser Pharmaceuticals Inc. (RBP)